Cancer cell microenvironment pH regulation (null)

The cancer cell microenvironment maintains an acidic extracellular pH (typically 6.5–7.1), distinct from normal tissue (pH 7.2–7.4), due to increased glycolysis (the Warburg effect) and lactate production, coupled with impaired proton/lactate removal. Cancer cells use a complex pH-regulatory apparatus—including ion exchangers (NHE1, Na+/K+ ATPase), monocarboxylate and bicarbonate transporters (MCTs, SLC4A1/A2/A3), and enzymes (carbonic anhydrase IX/XII)—to preserve intracellular alkalinity while acidifying their environment, which promotes migration, invasion, immune evasion, and abnormal angiogenesis. These adaptations are driven by genes responsive to hypoxia (HIF-1, HIF-2α), and supported by proton-sensing GPCRs and acid-sensing ion channels. Acidic TME disrupts immune cell function, augments matrix degradation, and facilitates the conversion of fibroblasts to cancer-associated fibroblasts (CAFs). Targeting pH regulatory mechanisms—through enzyme/transporter inhibition and buffering strategies—is an active area of therapeutic development, with clinical and experimental agents engaging these pathways[1][2][3][4][5][6][7].

Other names

Tumor microenvironment pH regulationTumor acidity regulationTumor acidosis responseAcidic TME adaptation

Enzyme inhibition: Blocking carbonic anhydrase IX disrupts bicarbonate and proton regulation. Transporter inhibition: Inhibiting MCTs and NHE1 blocks lactate/proton efflux and pH homeostasis. Buffering agents: Alkalinizing treatments (e.g., bicarbonate) neutralize TME acidity[2].